Xenon Pharmaceuticals (XENE) 10-Q8 Nov 222022 Q3 Quarterly reportFinancial data

Company Profile

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2022	Nov. 04, 2022
Cover [Abstract]
Entity Registrant Name	XENON PHARMACEUTICALS INC.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Common Stock, Shares Outstanding		62,544,019
Entity Central Index Key	0001582313
Entity Filer Category	Large Accelerated Filer
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Small Business	false
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity File Number	001-36687
Entity Tax Identification Number	98-0661854
Entity Address, Address Line One	200-3650 Gilmore Way
Entity Address, City or Town	Burnaby
Entity Address, State or Province	BC
Entity Address, Country	CA
Entity Address, Postal Zip Code	V5G 4W8
City Area Code	604
Local Phone Number	484-3300
Title of 12(b) Security	Common Shares, without par value
Trading Symbol	XENE
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	Z4
Document Quarterly Report	true
Document Transition Report	false

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 103,489	$ 175,688
Marketable securities (note 6)	534,696	376,086
Accounts receivable	2,482	2,765
Prepaid expenses and other current assets	8,509	4,481
Total current assets	649,176	559,020
Marketable securities, long-term (note 6)	113,989	0
Operating lease right-of-use asset, net (note 7)	7,559	8,056
Property, plant and equipment, net	4,575	4,466
Deferred tax assets	514	465
Total assets	775,813	572,007
Current liabilities:
Accounts payable and accrued expenses (note 8)	15,537	13,717
Operating lease liability (note 7)	0	605
Total current liabilities	15,537	14,322
Operating lease liability, long-term (note 7)	7,157	7,652
Total liabilities	22,694	21,974
Shareholders’ equity:
Preferred shares, without par value; unlimited shares authorized; issued and outstanding: nil (December 31, 2021 - 1,016,000) (note 9)	0	7,732
Common shares, without par value; unlimited shares authorized; issued and outstanding: 62,542,542 (December 31, 2021 - 51,634,752) (note 9)	1,064,698	783,170
Additional paid-in capital	136,728	117,495
Accumulated deficit	(445,352)	(357,374)
Accumulated other comprehensive loss	(2,955)	(990)
Total shareholders' equity	753,119	550,033
Total liabilities and shareholders’ equity	775,813	572,007
Commitments and contingencies (note 7 and note 11)

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Statement Of Financial Position [Abstract]
Preferred shares, without par value
Preferred shares, shares authorized	Unlimited	Unlimited
Preferred shares, issued	0	1,016,000
Preferred shares, outstanding	0	1,016,000
Common shares, without par value
Common shares, shares authorized	Unlimited	Unlimited
Common shares, Issued	62,542,542	51,634,752
Common shares, Outstanding	62,542,542	51,634,752

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenue (note 10)	$ 132	$ 8,124	$ 9,434	$ 14,700
Operating expenses:
Research and development	29,431	18,891	70,937	53,576
General and administrative	8,829	4,831	24,309	15,279
Total operating expenses	38,260	23,722	95,246	68,855
Loss from operations	(38,128)	(15,598)	(85,812)	(54,155)
Other income (expense):
Interest income	3,066	57	4,250	275
Unrealized fair value (loss) gain on trading securities	(294)	19	(4,944)	(72)
Foreign exchange (loss) gain	(2,381)	(128)	(2,493)	144
Other income (expense)	391	(52)	(3,187)	347
Loss before income taxes	(37,737)	(15,650)	(88,999)	(53,808)
Income tax recovery	587	205	1,021	490
Net loss	(37,150)	(15,445)	(87,978)	(53,318)
Net loss attributable to preferred shareholders	0	(362)	(420)	(1,308)
Net loss attributable to common shareholders	(37,150)	(15,083)	(87,558)	(52,010)
Other comprehensive loss:
Unrealized losses on available-for-sale securities (note 6)	(1,965)	0	(1,965)	0
Comprehensive loss	$ (39,115)	$ (15,445)	$ (89,943)	$ (53,318)
Net loss per common share (note 4):
Basic	$ (0.57)	$ (0.36)	$ (1.49)	$ (1.29)
Diluted	$ (0.57)	$ (0.36)	$ (1.49)	$ (1.29)
Weighted-average common shares outstanding (note 4):
Basic	65,465,069	42,274,348	58,836,928	40,396,391
Diluted	65,465,069	42,274,348	58,836,928	40,396,391

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Convertible Preferred Shares [Member]	Common Shares [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
Balance at Dec. 31, 2020	$ 171,355	$ 7,732	$ 397,748	$ 45,357	$ (278,492)	$ (990)
Balance (in Shares) at Dec. 31, 2020		1,016,000	35,012,125
Net loss	(15,764)				(15,764)
Issuance of common shares and pre-funded warrants, net of issuance costs (note 9a and note 9c)	118,615		$ 99,846	18,769
Issuance of common shares and pre-funded warrants, net of issuance costs (note 9a and note 9c) (in shares)			5,868,135
Stock-based compensation expense	1,965			1,965
Issued pursuant to exercise of stock options	106		$ 740	(634)
Issued pursuant to exercise of stock options (in Shares)			82,455
Balance at Mar. 31, 2021	276,277	$ 7,732	$ 498,334	65,457	(294,256)	(990)
Balance (in Shares) at Mar. 31, 2021		1,016,000	40,962,715
Balance at Dec. 31, 2020	171,355	$ 7,732	$ 397,748	45,357	(278,492)	(990)
Balance (in Shares) at Dec. 31, 2020		1,016,000	35,012,125
Net loss	$ (53,318)
Issued pursuant to exercise of stock options (in Shares)	386,708
Balance at Sep. 30, 2021	$ 248,939	$ 7,732	$ 504,386	69,621	(331,810)	(990)
Balance (in Shares) at Sep. 30, 2021		1,016,000	41,412,875
Balance at Mar. 31, 2021	276,277	$ 7,732	$ 498,334	65,457	(294,256)	(990)
Balance (in Shares) at Mar. 31, 2021		1,016,000	40,962,715
Net loss	(22,109)				(22,109)
Stock-based compensation expense	2,704			2,704
Issued pursuant to exercise of stock options	111		$ 1,017	(906)
Issued pursuant to exercise of stock options (in Shares)			154,853
Balance at Jun. 30, 2021	256,983	$ 7,732	$ 499,351	67,255	(316,365)	(990)
Balance (in Shares) at Jun. 30, 2021		1,016,000	41,117,568
Net loss	(15,445)				(15,445)
Issuance of common shares and pre-funded warrants, net of issuance costs (note 9a and note 9c)	4,730		$ 4,730
Issuance of common shares and pre-funded warrants, net of issuance costs (note 9a and note 9c) (in shares)			275,337
Stock-based compensation expense	2,643			2,643
Issued pursuant to exercise of stock options	$ 28		$ 305	(277)
Issued pursuant to exercise of stock options (in Shares)	41,974		19,970
Balance at Sep. 30, 2021	$ 248,939	$ 7,732	$ 504,386	69,621	(331,810)	(990)
Balance (in Shares) at Sep. 30, 2021		1,016,000	41,412,875
Balance at Dec. 31, 2021	550,033	$ 7,732	$ 783,170	117,495	(357,374)	(990)
Balance (in Shares) at Dec. 31, 2021		1,016,000	51,634,752
Net loss	(19,670)				(19,670)
Issuance of common shares and pre-funded warrants, net of issuance costs (note 9a and note 9c)	7,876		$ 7,876
Issuance of common shares and pre-funded warrants, net of issuance costs (note 9a and note 9c) (in shares)			258,986
Conversion of preferred shares to common shares (note 9b)		$ (7,732)	$ 7,732
Conversion of preferred shares to common shares (note 9b) (in shares)		(1,016,000)	1,016,000
Stock-based compensation expense	3,614			3,614
Issued pursuant to exercise of stock options			$ 1,529	(1,529)
Issued pursuant to exercise of stock options (in Shares)			149,311
Balance at Mar. 31, 2022	541,853		$ 800,307	119,580	(377,044)	(990)
Balance (in Shares) at Mar. 31, 2022			53,059,049
Balance at Dec. 31, 2021	550,033	$ 7,732	$ 783,170	117,495	(357,374)	(990)
Balance (in Shares) at Dec. 31, 2021		1,016,000	51,634,752
Net loss	$ (87,978)
Issued pursuant to exercise of stock options (in Shares)	718,472
Balance at Sep. 30, 2022	$ 753,119		$ 1,064,698	136,728	(445,352)	(2,955)
Balance (in Shares) at Sep. 30, 2022			62,542,542
Balance at Mar. 31, 2022	541,853		$ 800,307	119,580	(377,044)	(990)
Balance (in Shares) at Mar. 31, 2022			53,059,049
Net loss	(31,158)				(31,158)
Issuance of common shares and pre-funded warrants, net of issuance costs (note 9a and note 9c)	269,890		$ 260,503	9,387
Issuance of common shares and pre-funded warrants, net of issuance costs (note 9a and note 9c) (in shares)			9,098,362
Stock-based compensation expense	5,208			5,208
Issued pursuant to exercise of stock options			$ 880	(880)
Issued pursuant to exercise of stock options (in Shares)			85,472
Balance at Jun. 30, 2022	785,793	$ 0	$ 1,061,690	133,295	(408,202)	(990)
Balance (in Shares) at Jun. 30, 2022		0	62,242,883
Net loss	(37,150)				(37,150)
Stock-based compensation expense	5,742			5,742
Issued pursuant to exercise of stock options	$ 699		$ 3,008	(2,309)
Issued pursuant to exercise of stock options (in Shares)	369,334		299,659
Other comprehensive loss	$ (1,965)					(1,965)
Balance at Sep. 30, 2022	$ 753,119		$ 1,064,698	$ 136,728	$ (445,352)	$ (2,955)
Balance (in Shares) at Sep. 30, 2022			62,542,542

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating activities:
Net loss	$ (87,978)	$ (53,318)
Items not involving cash:
Depreciation	1,109	636
Deferred income tax recovery	(49)	(288)
Stock-based compensation	14,564	7,312
Unrealized foreign exchange loss	3,454	451
Unrealized fair value loss on trading securities	4,944	72
Changes in operating assets and liabilities:
Accounts receivable	242	(940)
Prepaid expenses and other current assets	(4,028)	(490)
Accounts payable and accrued expenses	2,044	(787)
Deferred revenue	0	(1,440)
Net cash used in operating activities	(65,698)	(48,792)
Investing activities:
Purchases of property, plant and equipment	(1,142)	(1,536)
Purchases of marketable securities	(436,393)	(132,280)
Proceeds from marketable securities	155,867	102,479
Net cash used in investing activities	(281,668)	(31,337)
Financing activities:
Issuance of common shares and pre-funded warrants, net of issuance costs (note 9a and note 9c)	277,766	123,345
Issuance of common shares pursuant to exercise of stock options	699	245
Net cash provided by financing activities	278,465	123,590
Effect of exchange rate changes on cash and cash equivalents	(3,298)	(661)
Increase (decrease) in cash and cash equivalents	(72,199)	42,800
Cash and cash equivalents, beginning of period	175,688	45,009
Cash and cash equivalents, end of period	103,489	87,809
Supplemental disclosures:
Interest received	6,206	2,428
Cash paid for operating lease	638	619
Supplemental disclosures of non-cash transactions:
Fair value of stock options exercised on a cashless basis	4,085	1,583
Increase in operating lease liability and accounts receivable related to lease incentives claimed in the period	$ 0	$ 493

Nature of the Business

Nature of the Business	9 Months Ended
Nature of the Business	Sep. 30, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of the Business	1. Nature of the business: Xenon Pharmaceuticals Inc. (the “Company”), incorporated in 1996 under the predecessor to the Business Corporations Act (British Columbia) and continued federally in 2000 under the Canada Business Corporations Act, is a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company has incurred significant operating losses since inception. As of September 30, 2022 , the Company had an accumulated deficit of $ 445,352 and a net loss of $ 87,978 for the nine months ended September 30, 2022. Management expects to continue to incur significant expenses in excess of revenue and to incur operating losses for the foreseeable future. To date, the Company has financed its operations primarily through the sale of equity securities, funding received from collaboration and license agreements, and debt financings. Until such time as the Company can generate substantial product revenue, if ever, management expects to finance the Company’s cash needs through a combination of collaboration agreements, equity and debt financings. The continuation of research and development activities and the future commercialization of its products are dependent on the Company’s ability to successfully raise additional funds when needed. It is not possible to predict either the outcome of future research and development programs or the Company’s ability to continue to fund these programs in the future.

Basis of Presentation

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	2. Basis of presentation: These unaudited interim consolidated financial statements are presented in U.S. dollars and include the accounts of the Company and its wholly-owned subsidiary, Xenon Pharmaceuticals USA Inc., a Delaware corporation. All intercompany transactions and balances have been eliminated on consolidation. Certain information has been reclassified to conform with the financial presentation adopted for the current year. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, these consolidated financial statements do not include all of the information and footnotes required for complete consolidated financial statements and should be read in conjunction with the audited consolidated financial statements and notes for the year ended December 31, 2021 included in the Company’s 2021 Annual Report on Form 10-K filed with the SEC and with the securities commissions in British Columbia, Alberta and Ontario on March 1, 2022. These unaudited interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three and nine month periods ended September 30, 2022 and 2021 are not necessarily indicative of results that can be expected for a full year. These unaudited interim consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company included in the Company’s 2021 Annual Report on Form 10-K for the year ended December 31, 2021 , with the exception of the policies described in note 3 below.

Changes in Significant Accounti

Changes in Significant Accounting Policies	9 Months Ended
Changes in Significant Accounting Policies	Sep. 30, 2022
Accounting Policies [Abstract]
Changes in Significant Accounting Policies	3. Changes in significant accounting policies: (a) Recently adopted accounting pronouncemen t: In June 2016, the Financial Accounting Standards Board issued Accounting Standards Update ("ASU") 2016-13 , Financial Instruments – Credit Losses (Topic 326). The standard adjusts the accounting for assets held at amortized cost basis, including marketable securities accounted for as available-for-sale. In vestors are required to determine whether a decline in the fair value below the amortized cost basis of the investment is due to credit-related factors. Credit-related impairment is recognized as an allowance for credit loss on the balance sheet with a corresponding adjustment to the consolidated statement of operations. Credit losses are limited to the amount by which the investment’s amortized cost basis exceeds its fair value and may be subsequently reversed if conditions change. Any impairment that is not credit related is recognized in other comprehensive income (loss), as applicable, net of applicable taxes. The ASU is effective for public business entities for fiscal years beginning after December 15, 2019. For all other entities, including smaller reporting companies as defined by the SEC, the standard is effective for fiscal years beginning after December 15, 2022. As the Company was a smaller reporting company on the date of assessment per the ASU and related amendments, adoption of this standard can be deferred to fiscal years beginning after December 15, 2022; however, the Company has elected to early adopt this ASU effective July 1, 2022 . The adoption did no t have a material impact on the Company’s consolidated financial statements. (b) Marketable securities: Marketable securities are debt securities with original maturities exceeding three months and accrue interest based on a fixed interest rate for the term. Effective July 1, 2022, the Company classifies its marketable securities as either trading securities or available-for-sale securities. Marketable securities are carried at fair value. Fair value gains and losses for marketable securities classified as trading securities are recorded through the consolidated statement of operations. These securities are classified as current assets as the Company has the intent and ability to convert these securities into cash without penalty within the next 12 months. Unrealized fair value gains and losses for marketable securities classified as available-for-sale are recorded through other comprehensive income (loss) in shareholders' equity. When the fair value of an available-for-sale security falls below the amortized cost basis it is evaluated to determine if any of the decline in value is attributable to credit loss. Decreases in fair value attributable to credit loss are recorded directly to the consolidated statement of operations with a corresponding allowance for credit losses, limited to the amount that the fair value is less than the amortized cost basis. If the credit quality subsequently improves the allowance is reversed up to a maximum of the previously recorded credit losses. When the Company intends to sell an impaired available-for-sale security, or if it is more likely than not that the Company will be required to sell the security prior to recovering the amortized cost basis, the entire fair value adjustment will immediately be recognized in the consolidated statement of operations with no corresponding allowance for credit losses. Realized gains and losses and credit losses, if any, on available-for-sale securities are included in interest income (expense), based on the specific identification method. Available-for-sale securities are also adjusted for amortization of premiums and accretion of discounts to maturity, with such amortization and accretion included within interest income. Available-for-sale securities with a remaining maturity date greater than one year are classified as non-current assets .

Net Income (Loss) Per Common Sh

Net Income (Loss) Per Common Share	9 Months Ended
Net Income (Loss) Per Common Share	Sep. 30, 2022
Earnings Per Share [Abstract]
Net Income (Loss) Per Common Share	4. Net income (loss) per common share: Basic net income (loss) per common share is calculated using the two-class method required for participating securities which includes the Series 1 Preferred Shares as a separate class for the nine months ended September 30, 2022, and for the three and nine months ended September 30, 2021. The convertible preferred shares entitle the holders to participate in dividends and in earnings and losses of the Company on an equivalent basis as common shares. Accordingly, undistributed earnings (losses) are allocated to common shares and participating preferred shares based on the weighted-average shares of each class outstanding during the period. In March 2022, the outstanding 1,016,000 Series 1 Preferred Shares were converted and exchanged for an equal number of common shares of the Company (note 9b). The weighted average number of common shares used in the basic and diluted net income (loss) per common share calculations includes the weighted-average pre-funded warrants outstanding during the period as they are exercisable at any time for nominal cash consideration. The treasury stock method is used to compute the dilutive effect of the Company’s stock options and warrants. Under this method, the incremental number of common shares used in computing diluted net income (loss) per common share is the difference between the number of common shares assumed issued and purchased using assumed proceeds. The if-converted method is used to compute the dilutive effect of the Company’s convertible preferred shares. Under the if-converted method, dividends on the preferred shares, if applicable, are added back to earnings attributable to common shareholders, and the preferred shares and paid-in kind dividends are assumed to have been converted at the share price applicable at the end of the period. The if-converted method is applied only if the effect is dilutive. For the three and nine months ended September 30, 2022 and 2021, diluted net loss per share attributable to common shareholders is the same as basic net loss per share attributable to common shareholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
Fair Value of Financial Instruments	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	5. Fair value of financial instrument s: The Company measures certain financial instruments and other items at fair value. To determine the fair value, the Company uses the fair value hierarchy for inputs used to measure fair value of financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority). • Level 1 - Unadjusted quoted prices in active markets for identical instruments. • Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). • Level 3 - Inputs are unobservable and reflect the Company’s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available. Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The carrying amount of accounts receivable, accounts payable and accrued expenses approximates fair values due to the nature and short term of those instruments. The Company’s cash and cash equivalents and marketable securities are measured at fair value on a recurring basis. The level of the fair value hierarchy utilized to determine such fair values consisted of the following: September 30, 2022 December 31, 2021 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Cash and cash equivalents Cash and money market fund $ 70,904 $ — $ — $ 70,904 $ 175,688 $ — $ — $ 175,688 Commercial paper — 20,452 — 20,452 — — — — Corporate debt securities — 12,133 — 12,133 — — — — Marketable securities Guaranteed investment certificates 14,491 — — 14,491 — — — — U.S. government securities 376,777 — — 376,777 239,057 — — 239,057 Commercial paper — 102,465 — 102,465 — — — — Corporate debt securities — 154,952 154,952 — 137,029 — 137,029 Total $ 462,172 $ 290,002 $ — $ 752,174 $ 414,745 $ 137,029 $ — $ 551,774 The fair values of the Company’s commercial paper and corporate debt securities are based on prices obtained from independent pricing sources. Securities with validated quotes from pricing services are reflected within Level 2, as they are primarily based on observable pricing for similar assets or other market observable inputs. Typical inputs used by these pricing services include, but are not limited to, reported trades, benchmark yields, issuer spreads, bids, offers or estimates of cash flow, prepayment spreads and default rates. As of September 30, 2022 and December 31, 2021, the Company does not hold any securities classified as Level 3, which are securities valued using unobservable inputs.

Marketable Securities

Marketable Securities	9 Months Ended
Marketable Securities	Sep. 30, 2022
Investments Debt And Equity Securities [Abstract]
Marketable Securities	6. Marketable securities As of September 30, 2022, the Company had $ 355,543 of trading securities and $ 293,142 of available-for-sale securities (December 31, 2021 – $ 376,086 and nil, respectively). Amortized cost, unrealized losses recognized in accumulated other comprehensive income (loss) and fair value of available-for-sale securities consisted of the following: September 30, 2022 Amortized Unrealized Fair Contractual maturity of 0 to 1 years: Guaranteed investment certificates $ 14,491 $ — $ 14,491 U.S. government securities 53,875 ( 465 ) 53,410 Commercial paper 102,465 — 102,465 Corporate debt securities 8,866 ( 79 ) 8,787 Contractual maturity of 1 to 3 years: U.S. government securities 72,775 ( 1,225 ) 71,550 Corporate debt securities 42,635 ( 196 ) 42,439 Total $ 295,107 $ ( 1,965 ) $ 293,142 Allowance for credit losses or impairment on these marketable securities have not been recognized as these securities are high credit quality, investment grade securities that the Company does not intend to sell and will not be required to sell prior to their anticipated recovery, and the decline in fair value is primarily due to changes in interest rates.

Leases

Leases	9 Months Ended
Leases	Sep. 30, 2022
Leases [Abstract]
Leases	7. Leases: The Company has one operating lease for research laboratories and office space in Burnaby, British Columbia. In October 2020, the Company entered into a lease amendment for a 21-month committed term from October 1, 2020 to June 30, 2022 and a renewal option for a portion of the facility for a 5-year term that was reasonably certain of exercise was included in the determination of the right-of-use asset and lease liability. In November 2021, the Company entered into an agreement to extend the lease for an additional 10-year term to June 30, 2032 . The cost components of the operating lease were as follows for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Lease Cost Operating lease expense $ 238 $ 140 $ 714 $ 419 Variable lease expense (1) 195 185 578 559 Lease Term and Discount Rate Remaining lease term (years) 9.75 5.75 9.75 5.75 Discount rate 3.42 % 2.45 % 3.42 % 2.45 % (1) Variable lease costs are payments that vary because of changes in facts or circumstances and include common area maintenance and property taxes related to the premises. Variable lease costs are excluded from the calculation of minimum lease payments. Future minimum lease payments as of September 30, 2022 were as follows: Year ending December 31: 2022 $ 213 2023 852 2024 890 2025 940 2026 990 2027 and thereafter 6,210 Total future minimum lease payments $ 10,095 Less: imputed interest ( 1,596 ) Less: future lease incentives reasonably certain of use (1) ( 1,342 ) Present value of lease liabilities $ 7,157 (1) The future lease incentives are expected to be utilized within the next twelve months. In July 2022, the Company entered into a lease agreement for office space in Needham, Massachusetts. As of September 30, 2022, the lease has not yet commenced; the Company began occupying the premise in October 2022. The base rent will range from $ 751 to $ 819 annually over a five-year lease term.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	9 Months Ended
Accounts Payable and Accrued Expenses	Sep. 30, 2022
Payables And Accruals [Abstract]
Accounts Payable and Accrued Expenses	8. Accounts payable and accrued expenses: Accounts payable and accrued expenses consisted of the following: September 30, December 31, 2022 2021 Trade payables $ 3,082 $ 3,824 Employee compensation, benefits, and related accruals 4,221 5,940 Consulting and contracted research 7,220 3,550 Professional fees 969 285 Other 45 118 Total $ 15,537 $ 13,717

Share Capital

Share Capital	9 Months Ended
Share Capital	Sep. 30, 2022
Stockholders Equity Note [Abstract]
Share Capital	9. Share capital: (a) Financing: In August 2020, the Company entered into an “at-the-market” equity offering sales agreement, amended as of March 2022, with Jefferies LLC (“Jefferies”) and Stifel, Nicolaus & Company, Incorporated (“Stifel”) pursuant to which the Company may sell common shares from time to time. In January 2021, the Company sold an aggregate of 733,000 common shares for proceeds of $ 10,693 , net of commissions and transaction expenses pursuant to a prospectus supplement filed in August 2020 (“August 2020 ATM"). The Company may sell common shares having gross proceeds of up to $ 250,000 , from time to time, pursuant to a new prospectus supplement filed in March 2022 (“March 2022 ATM"), replacing the August 2020 ATM. As of September 30, 2022, no common shares have been sold under the March 2022 ATM. In March 2021, the Company entered into an underwriting agreement with Jefferies and Stifel, relating to an underwritten public offering of 5,135,135 common shares, including 810,810 common shares sold upon the full exercise of the underwriters’ over-allotment option, at a public offering price of $ 18.50 per common share and pre-funded warrants to purchase 1,081,081 common shares at $ 18.4999 per pre-funded warrant ( note 9c ), with each pre-funded warrant having an exercise price of $ 0.0001 . The public offering was completed in March 2021, and the Company received proceeds of $ 107,922 , net of underwriting discounts, commissions and offering expenses. In September 2021, in connection with the License and Collaboration Agreement with Neurocrine Biosciences Inc. (“Neurocrine Biosciences”) entered in December 2019 and amended in January 2021 (the "Neurocrine Collaboration Agreement"), the Company executed a Share Purchase Agreement ("SPA") pursuant to which the Company issued 275,337 common shares for an aggregate purchase price of $ 5,500 , or $ 19.9755 per common share, which represents a premium of $ 770 when measured at fair value on the date of issuance. In addition, in January 2022, the Company executed a SPA pursuant to which the Company issued 258,986 common shares for an aggregate purchase price of $ 8,250 , or $ 31.855 per common share, which represents a premium of $ 374 when compared to the fair value of common shares on the date of issuance. The SPAs contain certain other customary terms and conditions, including mutual representations, warranties and covenants. For additional information regarding the Neurocrine Collaboration Agreement, refer to note 10a. In June 2022, the Company entered into an underwriting agreement with Jefferies, J.P. Morgan Securities LLC, Stifel and SVB Securities LLC, relating to an underwritten public offering of 9,098,362 common shares, including 1,229,508 shares sold upon the full exercise of the underwriters’ over-allotment option, at a public offering price of $ 30.50 per common share and pre-funded warrants to purchase 327,868 common shares at $ 30.4999 per pre-funded warrant ( note 9c ), with each pre-funded warrant having an exercise price of $ 0.0001 . The public offering was completed in June 2022, and the Company received proceeds of $ 269,890 , net of underwriting discounts, commissions and offering expenses. (b) Exchange agreement with certain funds affiliated with BVF Partners L.P. (collectively, “BVF”): In March 2018, the Company and BVF entered into an exchange agreement pursuant to which the Company issued to BVF 2,868,000 Series 1 Preferred Shares in exchange for 2,868,000 common shares which were subsequently cancelled by the Company. The Series 1 Preferred Shares were convertible into common shares on a one-for-one basis, subject to certain restrictions. The Series 1 Preferred Shares ranked equally to the common shares in the event of liquidation, dissolution or winding up or other distribution of the assets of the Company among its shareholders and the holders of the Series 1 Preferred Shares were entitled to vote together with the common shares on an as-converted basis and as a single class, subject to certain restrictions. The Series 1 Preferred Shares were recorded wholly as equity under ASC 480, with no bifurcation of conversion feature from the host contract, given that the Series 1 Preferred Shares cannot be cash settled and had no redemption features. During the year ended December 31, 2018, BVF converted 1,852,000 Series 1 Preferred Shares in exchange for an equal number of common shares. In March 2022, the remaining outstanding 1,016,000 Series 1 Preferred Shares were exchanged for an equal number of common shares. (c) Pre-funded warrants: The following table summarizes the pre-funded warrants outstanding at September 30, 2022: Date of Issuance Pre-Funded Warrants to Purchase Common Shares Price per Pre-Funded Warrant Exercise Price March 2021 1,081,081 $ 18.4999 $ 0.0001 October 2021 1,694,915 $ 29.4999 $ 0.0001 June 2022 327,868 $ 30.4999 $ 0.0001 Total 3,103,864 The pre-funded warrants are exercisable at the holder’s discretion from the date of issuance until the date the pre-funded warrant is exercised in full. The Company may not affect the exercise of any pre-funded warrant, and a holder will not be entitled to exercise any portion of any pre-funded warrant that, upon giving effect to such exercise, would cause: (i) the aggregate number of common shares beneficially owned by such holder, together with its affiliates, to exceed 4.99% of the total number of common shares outstanding immediately after giving effect to the exercise; or (ii) the combined voting power of the Company’s securities beneficially owned by such holder, together with its affiliates, to exceed 4.99% of the combined voting power of all of the Company’s securities immediately outstanding after giving effect to the exercise, which percentage may be changed at the holder’s election to a higher or lower percentage not in excess of 19.99% upon at least 61 days’ notice to the Company. Since the pre-funded warrants meet the condition for equity classification, net proceeds from issuances of the pre-funded warrants are recorded in additional paid-in capital. Upon exercise of the pre-funded warrants, the historical costs recorded in additional paid-in capital along with the exercise price collected from holder will be recorded in common shares. As of September 30, 2022, no pre-funded warrants have been exercised. Pre-funded warrants to purchase 3,103,864 (September 30, 2021 – 1,081,081 ) common shares are not included in the number of issued and outstanding common shares as of September 30, 2022. (d) Stock-based compensation: The following table presents stock option activity for the period: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Outstanding, beginning of period 7,234,460 5,771,051 5,638,232 4,758,997 Granted 102,000 236,200 2,079,845 1,730,650 Exercised (1) ( 369,334 ) ( 41,974 ) ( 718,472 ) ( 386,708 ) Forfeited, cancelled or expired ( 21,357 ) ( 45,843 ) ( 53,836 ) ( 183,505 ) Outstanding, end of period 6,945,769 5,919,434 6,945,769 5,919,434 Exercisable, end of period 3,391,011 3,068,278 3,391,011 3,068,278 (1) During the nine months ended September 30, 2022 , 65,844 stock options were exercised for cash ( nine months ended September 30, 2021 – 61,072 ). In the same period, the Company issued 468,598 ( nine months ended September 30, 2021 – 196,206 ) common shares for the cashless exercise of 652,628 ( nine months ended September 30, 2021 – 325,636 ) stock options. The fair value of each stock option granted is estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Average risk-free interest rate 3.20 % 1.00 % 2.19 % 1.16 % Expected volatility 70 % 68 % 70 % 68 % Average expected term (in years) 4.92 6.77 6.15 6.69 Expected dividend yield 0 % 0 % 0 % 0 % Weighted average fair value of stock options granted $ 21.63 $ 10.74 $ 19.40 $ 12.41

Revenue

Revenue	9 Months Ended
Revenue	Sep. 30, 2022
Revenue From Contract With Customer [Abstract]
Revenue	10. Revenue: Revenue was as follows for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Neurocrine Biosciences: Recognition of the transaction price $ — $ 823 $ 372 $ 1,440 Research and development services 132 2,031 1,938 4,990 Milestone payments — 5,270 7,124 5,270 Pacira BioSciences: Milestone payments — — — 3,000 Total collaboration revenue $ 132 $ 8,124 $ 9,434 $ 14,700 (a) Neurocrine Biosciences license and collaboration agreement: In December 2019, the Company entered into the Neurocrine Collaboration Agreement with Neurocrine Biosciences. Pursuant to this agreement, the Company granted an exclusive license to XEN901, now known as NBI-921352, and an exclusive license to pre-clinical compounds for development, XEN393, XPC’535 and XPC’391 (collectively, the “DTCs”). The agreement also includes a two-year research collaboration to discover, identify and develop additional novel Nav1.6 and Nav1.2/1.6 inhibitors (“Research Compounds”) which ended in June 2022. The Company and Neurocrine Biosciences are collaborating on the conduct of two collaboration programs: (a) a joint research collaboration to discover, identify and preclinically develop Research Compounds (the “Research Program”) and (b) a collaborative development program for NBI-921352 and two DTCs selected by the joint steering committee (the “Initial Development Program”). At execution of the agreement, Neurocrine Biosciences paid the Company an upfront cash payment of $ 30,000 and a $ 20,000 equity investment in the Company. The equity investment was measured at fair value of $ 16,667 on the date of issuance and the resulting premium of $ 3,333 , together with the upfront cash payment totaling $ 33,333 , was the transaction price of the arrangement for allocation to the performance obligations. The agreement includes the following performance obligations: (i) an exclusive license to NBI-921352 with associated technology and know-how transfer, (ii) an exclusive license to the DTCs with associated know-how transfer, (iii) a license to Research Compounds and research services under the Research Program, (iv) development services under the Initial Development Program for NBI-921352, and (v) development services under the Initial Development Program for the DTCs. The total transaction price of $ 33,333 was allocated to performance obligation (v) based on its estimated standalone selling price determined based on internal development plans and budget, with the balance allocated to performance obligations (i) and (ii) by the residual approach. The Company allocated the transaction price as follows: $ 28,807 to performance obligations (i) and (ii), completed as of December 2020, and $ 5,025 , which includes $ 499 of variable consideration, to performance obligation (v), which was completed as of March 2022. The arrangement consideration related to the services under performance obligations (iii) and (iv) to be performed on behalf of Neurocrine Biosciences were excluded from the initial transaction price allocation because the consideration and performance are contingent upon Neurocrine Biosciences requesting performance of the services and these services are priced at an estimated fair value. None of the at-risk substantive performance milestones, including development, regulatory and sales-based milestones, were included in the transaction price at the inception of the agreement, as all milestone amounts are outside the control of the Company and contingent upon Neurocrine Biosciences’s efforts and success in future clinical trials. In September 2021, based on the regulatory approval of a clinical trial application in Europe for NBI-921352 for focal-onset seizures in adults, the Company received an aggregate milestone payment of $ 10,000 in the form of $ 4,500 in cash and a $ 5,500 equity investment in the Company (note 9a). The equity investment was measured at fair value of $ 4,730 on the date of issuance and the resulting premium of $ 770 , with the cash payment of $ 4,500 , was recognized as revenue in the period as the Company did no t have any remaining performance obligations in relation to this milestone on the date it was achieved. In January 2022, based on the receipt of the U.S. Food and Drug Administration’s (“FDA”) full IND acceptance for NBI-921352, the Company received an aggregate milestone payment of $ 15,000 in the form of $ 6,750 in cash and a $ 8,250 equity investment in the Company (note 9a) . The equity investment was measured at fair value of $ 7,876 on the date of issuance and the resulting premium of $ 374 , with the cash payment of $ 6,750 , was recognized as revenue in the period as the Company did no t have any remaining performance obligations in relation to this milestone on the date it was achieved. During the three and nine months ended September 30, 2022, the Company recognized $ 132 and $ 1,938 of revenue, respectively, for the research and development services under (iii) the Research Program and (iv) the Initial Development Program for NBI-921352, compared to $ 2,031 and $ 4,990 for the three and nine months ended September 30, 2021, respectively. In addition, the Company recognized nil and $ 372 for the three and nine months ended September 30, 2022, respectively, for (v) development services under the Initial Development Program for the DTCs, compared to $ 823 and $ 1,440 for the three and nine months ended September 30, 2021, respectively. The Company is eligible to receive pre-commercial and commercial milestone payments with respect to the licensed products totaling up to an additional $ 1,667,500 , comprised of up to $ 1,067,500 in additional development and regulatory milestone payments related to NBI-921352 and other licensed Nav1.6 or Nav1.2/1.6 inhibitor products, and up to $ 600,000 in additional sales-based milestone payments for multiple products. In addition, the Company is eligible to receive royalties on net sales in and outside the U.S., ranging from (a) for NBI-921352, a low double-digit percentage to a mid-teen percentage and a high-single digit percentage to low double-digit percentage, respectively; (b) for DTCs, a high-single digit percentage to a low double-digit percentage and a mid-single digit percentage to a high-single digit percentage, respectively; and (c) for Research Compounds, a mid-single digit percentage to a high-single digit percentage and a tiered mid-single digit percentage, respectively. Royalty rates are subject to customary reductions. These additional amounts will be recognized as determinable. The Company has an option to co-fund 50 % of the development costs of NBI-921352 or another product candidate in the U.S., exercisable upon achievement of certain milestones, in exchange for increased U.S. royalties. The Company has not exercised this option as of September 30, 2022. (b) Asset Purchase Agreement with Flexion Therapeutics, Inc., which was subsequently acquired by Pacira BioSciences, Inc. In September 2019, the Company entered into an agreement with Flexion Therapeutics Inc. (“Flexion”), which was acquired by Pacira BioSciences, Inc. (“Pacira BioSciences”) in November 2021, pursuant to which Flexion acquired all rights with respect to XEN402, and a related compound (collectively “XEN402”), including certain regulatory documentation, intellectual property rights, reports, data and all quantities of XEN402, now known as PCRX-301, owned or controlled by the Company. During the nine months ended September 30, 2021, the FDA cleared the first investigational new drug application for PCRX-301 and Flexion initiated a Phase 1b clinical trial, resulting in milestone payments of $ 1,000 and $ 2,000 paid to the Company, respectively. In November 2022, Pacira BioSciences made the strategic decision to no longer pursue the clinical development of PCRX-301.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2022
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and contingencies: (a) Priority access agreement with Medpace Inc. (“Medpace”): In August 2015, the Company entered into a priority access agreement with Medpace for the provision of certain clinical development services, under which the Company has committed to using Medpace non-exclusively for clinical development services over the five-year term of the agreement which ended in August 2020. The Company has committed to $ 7,000 of services over the term of the agreement of which $ 5,521 of services have been received and $ 1,479 remains committed as of September 30, 2022. As the Company did not meet the commitment to retain Medpace for $7,000 of services prior to August 2020, the Company is required to provide Medpace the exclusive right to perform all subsequent outsourced clinical development work until such $7,000 commitment has been satisfied, subject to the availability of appropriate Medpace resources and reasonable service rates. If the Company decides not to retain Medpace for the provision of clinical development services, the Company may satisfy its obligations under the priority access agreement by paying Medpace an amount equal to half of the unsatisfied portion. The Company intends to continue to utilize Medpace for clinical development work where suitable in order to fulfill the remaining commitment; therefore, no liability has been recognized as of September 30, 2022 with respect to the unsatisfied portion under the priority access agreement. (b) Asset purchase agreement with 1st Order Pharmaceuticals, Inc. (“1st Order”): In April 2017, the Company acquired XEN1101 (previously known as 1OP2198) from 1st Order pursuant to an asset purchase agreement. In August 2020, the Company and 1st Order amended the asset purchase agreement to amend certain definitions in the agreement and to modify the payment schedule for certain milestones. Future potential payments to 1st Order related to the XEN1101 program include up to $ 900 in clinical development milestones, up to $ 6,000 in regulatory milestones, and $ 500 in other milestones. To date, the Company has paid $ 600 based on progress against these milestones. There are no royalty obligations to 1st Order. (c) Guarantees and indemnifications: The Company has entered into license and research agreements with third parties that include indemnification provisions that are customary in the industry. These indemnification provisions generally require the Company to compensate the other party for certain damages and costs incurred as a result of third-party claims or damages arising from these transactions. The maximum amount of potential future indemnification is unlimited; however, the Company currently holds commercial and product liability insurance. This insurance limits the Company’s exposure and may enable it to recover a portion of any future amounts paid. Historically, the Company has not made any indemnification payments under such agreements and the Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.

Changes in Significant Accoun_2

Changes in Significant Accounting Policies (Policies)	9 Months Ended
Changes in Significant Accounting Policies (Policies)	Sep. 30, 2022
Accounting Policies [Abstract]
Recently Adopted Accounting Pronouncement	(a) Recently adopted accounting pronouncemen t: In June 2016, the Financial Accounting Standards Board issued Accounting Standards Update ("ASU") 2016-13 , Financial Instruments – Credit Losses (Topic 326). The standard adjusts the accounting for assets held at amortized cost basis, including marketable securities accounted for as available-for-sale. In vestors are required to determine whether a decline in the fair value below the amortized cost basis of the investment is due to credit-related factors. Credit-related impairment is recognized as an allowance for credit loss on the balance sheet with a corresponding adjustment to the consolidated statement of operations. Credit losses are limited to the amount by which the investment’s amortized cost basis exceeds its fair value and may be subsequently reversed if conditions change. Any impairment that is not credit related is recognized in other comprehensive income (loss), as applicable, net of applicable taxes. The ASU is effective for public business entities for fiscal years beginning after December 15, 2019. For all other entities, including smaller reporting companies as defined by the SEC, the standard is effective for fiscal years beginning after December 15, 2022. As the Company was a smaller reporting company on the date of assessment per the ASU and related amendments, adoption of this standard can be deferred to fiscal years beginning after December 15, 2022; however, the Company has elected to early adopt this ASU effective July 1, 2022 . The adoption did no t have a material impact on the Company’s consolidated financial statements.
Marketable Securities	(b) Marketable securities: Marketable securities are debt securities with original maturities exceeding three months and accrue interest based on a fixed interest rate for the term. Effective July 1, 2022, the Company classifies its marketable securities as either trading securities or available-for-sale securities. Marketable securities are carried at fair value. Fair value gains and losses for marketable securities classified as trading securities are recorded through the consolidated statement of operations. These securities are classified as current assets as the Company has the intent and ability to convert these securities into cash without penalty within the next 12 months. Unrealized fair value gains and losses for marketable securities classified as available-for-sale are recorded through other comprehensive income (loss) in shareholders' equity. When the fair value of an available-for-sale security falls below the amortized cost basis it is evaluated to determine if any of the decline in value is attributable to credit loss. Decreases in fair value attributable to credit loss are recorded directly to the consolidated statement of operations with a corresponding allowance for credit losses, limited to the amount that the fair value is less than the amortized cost basis. If the credit quality subsequently improves the allowance is reversed up to a maximum of the previously recorded credit losses. When the Company intends to sell an impaired available-for-sale security, or if it is more likely than not that the Company will be required to sell the security prior to recovering the amortized cost basis, the entire fair value adjustment will immediately be recognized in the consolidated statement of operations with no corresponding allowance for credit losses. Realized gains and losses and credit losses, if any, on available-for-sale securities are included in interest income (expense), based on the specific identification method. Available-for-sale securities are also adjusted for amortization of premiums and accretion of discounts to maturity, with such amortization and accretion included within interest income. Available-for-sale securities with a remaining maturity date greater than one year are classified as non-current assets .

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
Fair Value of Financial Instruments (Tables)	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Financial Assets Measured at Fair Value on a Recurring Basis	The level of the fair value hierarchy utilized to determine such fair values consisted of the following: September 30, 2022 December 31, 2021 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Cash and cash equivalents Cash and money market fund $ 70,904 $ — $ — $ 70,904 $ 175,688 $ — $ — $ 175,688 Commercial paper — 20,452 — 20,452 — — — — Corporate debt securities — 12,133 — 12,133 — — — — Marketable securities Guaranteed investment certificates 14,491 — — 14,491 — — — — U.S. government securities 376,777 — — 376,777 239,057 — — 239,057 Commercial paper — 102,465 — 102,465 — — — — Corporate debt securities — 154,952 154,952 — 137,029 — 137,029 Total $ 462,172 $ 290,002 $ — $ 752,174 $ 414,745 $ 137,029 $ — $ 551,774

Marketable Securities (Tables)

Marketable Securities (Tables)	9 Months Ended
Marketable Securities (Tables)	Sep. 30, 2022
Investments Debt And Equity Securities [Abstract]
Summary of Amortized Cost, Unrealized Losses Recognized in AOCI and Fair Value of Available-for-Sale Securities	Amortized cost, unrealized losses recognized in accumulated other comprehensive income (loss) and fair value of available-for-sale securities consisted of the following: September 30, 2022 Amortized Unrealized Fair Contractual maturity of 0 to 1 years: Guaranteed investment certificates $ 14,491 $ — $ 14,491 U.S. government securities 53,875 ( 465 ) 53,410 Commercial paper 102,465 — 102,465 Corporate debt securities 8,866 ( 79 ) 8,787 Contractual maturity of 1 to 3 years: U.S. government securities 72,775 ( 1,225 ) 71,550 Corporate debt securities 42,635 ( 196 ) 42,439 Total $ 295,107 $ ( 1,965 ) $ 293,142

Leases (Tables)

Leases (Tables)	9 Months Ended
Leases (Tables)	Sep. 30, 2022
Leases [Abstract]
Schedule of Cost Components of Operating Lease	The cost components of the operating lease were as follows for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Lease Cost Operating lease expense $ 238 $ 140 $ 714 $ 419 Variable lease expense (1) 195 185 578 559 Lease Term and Discount Rate Remaining lease term (years) 9.75 5.75 9.75 5.75 Discount rate 3.42 % 2.45 % 3.42 % 2.45 % (1) Variable lease costs are payments that vary because of changes in facts or circumstances and include common area maintenance and property taxes related to the premises. Variable lease costs are excluded from the calculation of minimum lease payments.
Future Minimum Lease Payments	Future minimum lease payments as of September 30, 2022 were as follows: Year ending December 31: 2022 $ 213 2023 852 2024 890 2025 940 2026 990 2027 and thereafter 6,210 Total future minimum lease payments $ 10,095 Less: imputed interest ( 1,596 ) Less: future lease incentives reasonably certain of use (1) ( 1,342 ) Present value of lease liabilities $ 7,157 (1) The future lease incentives are expected to be utilized within the next twelve months.

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	9 Months Ended
Accounts Payable and Accrued Expenses (Tables)	Sep. 30, 2022
Payables And Accruals [Abstract]
Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses consisted of the following: September 30, December 31, 2022 2021 Trade payables $ 3,082 $ 3,824 Employee compensation, benefits, and related accruals 4,221 5,940 Consulting and contracted research 7,220 3,550 Professional fees 969 285 Other 45 118 Total $ 15,537 $ 13,717

Share Capital (Tables)

Share Capital (Tables)	9 Months Ended
Share Capital (Tables)	Sep. 30, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Pre-Funded Warrants Outstanding	The following table summarizes the pre-funded warrants outstanding at September 30, 2022: Date of Issuance Pre-Funded Warrants to Purchase Common Shares Price per Pre-Funded Warrant Exercise Price March 2021 1,081,081 $ 18.4999 $ 0.0001 October 2021 1,694,915 $ 29.4999 $ 0.0001 June 2022 327,868 $ 30.4999 $ 0.0001 Total 3,103,864
Stock Option Activity	The following table presents stock option activity for the period: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Outstanding, beginning of period 7,234,460 5,771,051 5,638,232 4,758,997 Granted 102,000 236,200 2,079,845 1,730,650 Exercised (1) ( 369,334 ) ( 41,974 ) ( 718,472 ) ( 386,708 ) Forfeited, cancelled or expired ( 21,357 ) ( 45,843 ) ( 53,836 ) ( 183,505 ) Outstanding, end of period 6,945,769 5,919,434 6,945,769 5,919,434 Exercisable, end of period 3,391,011 3,068,278 3,391,011 3,068,278 (1) During the nine months ended September 30, 2022 , 65,844 stock options were exercised for cash ( nine months ended September 30, 2021 – 61,072 ). In the same period, the Company issued 468,598 ( nine months ended September 30, 2021 – 196,206 ) common shares for the cashless exercise of 652,628 ( nine months ended September 30, 2021 – 325,636 ) stock options.
Fair Value Assumptions for Stock Options	The fair value of each stock option granted is estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Average risk-free interest rate 3.20 % 1.00 % 2.19 % 1.16 % Expected volatility 70 % 68 % 70 % 68 % Average expected term (in years) 4.92 6.77 6.15 6.69 Expected dividend yield 0 % 0 % 0 % 0 % Weighted average fair value of stock options granted $ 21.63 $ 10.74 $ 19.40 $ 12.41

Revenue (Tables)

Revenue (Tables)	9 Months Ended
Revenue (Tables)	Sep. 30, 2022
Revenue From Contract With Customer [Abstract]
Schedule Of Collaboration Revenue	Revenue was as follows for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Neurocrine Biosciences: Recognition of the transaction price $ — $ 823 $ 372 $ 1,440 Research and development services 132 2,031 1,938 4,990 Milestone payments — 5,270 7,124 5,270 Pacira BioSciences: Milestone payments — — — 3,000 Total collaboration revenue $ 132 $ 8,124 $ 9,434 $ 14,700

Nature of the Business (Details

Nature of the Business (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
Nature of the Business (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Accumulated deficit	$ 445,352						$ 445,352		$ 357,374
Net loss	$ 37,150	$ 31,158	$ 19,670	$ 15,445	$ 22,109	$ 15,764	$ 87,978	$ 53,318

Changes in Significant Accoun_3

Changes in Significant Accounting Policies (Details)	3 Months Ended
Changes in Significant Accounting Policies (Details)	Sep. 30, 2022
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in accounting principle, early adoption	true
Change in accounting principle, adoption date	Jul. 01, 2022
Change in accounting principle, material impact	true
Change in Accounting Principle, Accounting Standards Update, Transition Option Elected [Extensible Enumeration]	us-gaap:AccountingStandardsUpdate201613Member

Net Income (Loss) Per Common _2

Net Income (Loss) Per Common Share (Details)	1 Months Ended
Net Income (Loss) Per Common Share (Details)	Mar. 31, 2022 shares
Series 1 Preferred Shares
Class Of Stock [Line Items]
Preferred shares, converted	1,016,000

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of Financial Assets Measured at Fair Value on a Recurring Basis (Details) - Recurring Basis [Member] - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]
Financial assets	$ 752,174	$ 551,774
Cash and Money Market Fund [Member]
Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]
Cash and cash equivalents	70,904	175,688
Commercial Paper [Member]
Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]
Cash and cash equivalents	20,452
Financial assets	102,465
Guaranteed Investment Certificates [Member]
Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]
Financial assets	14,491
U.S. Government Securities [Member]
Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]
Financial assets	376,777	239,057
Corporate Debt Securities [Member]
Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]
Cash and cash equivalents	12,133
Financial assets	154,952	137,029
Level 1 [Member]
Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]
Financial assets	462,172	414,745
Level 1 [Member] \| Cash and Money Market Fund [Member]
Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]
Cash and cash equivalents	70,904	175,688
Level 1 [Member] \| Guaranteed Investment Certificates [Member]
Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]
Financial assets	14,491
Level 1 [Member] \| U.S. Government Securities [Member]
Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]
Financial assets	376,777	239,057
Level 2 [Member]
Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]
Financial assets	290,002	137,029
Level 2 [Member] \| Commercial Paper [Member]
Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]
Cash and cash equivalents	20,452
Financial assets	102,465
Level 2 [Member] \| Corporate Debt Securities [Member]
Financial Assets Measured at Fair Value on a Recurring Basis [Line Items]
Cash and cash equivalents	12,133
Financial assets	$ 154,952	$ 137,029

Marketable Securities - Additio

Marketable Securities - Additional Information (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Investments Debt And Equity Securities [Abstract]
Trading marketable securities	$ 355,543	$ 376,086
Trading securities available-for-sale	$ 293,142

Marketable Securities - Summary

Marketable Securities - Summary of Amortized Cost, Unrealized Losses Recognized in AOCI and Fair Value of Available-for-Sale Securities (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 295,107
Unrealized Loss	(1,965)
Fair Value	293,142
Guaranteed Investment Certificates [Member]
Schedule Of Available For Sale Securities [Line Items]
Contractual maturity of 0 to 1 years, Amortized Cost	14,491
Contractual maturity of 0 to 1 years, Fair Value	14,491
U.S. Government Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Contractual maturity of 0 to 1 years, Amortized Cost	53,875
Contractual maturity of 0 to 1 years, Unrealized Loss	(465)
Contractual maturity of 0 to 1 years, Fair Value	53,410
Contractual maturity of 1 to 3 years, Amortized Cost	72,775
Contractual maturity of 1 to 3 years, Unrealized Loss	(1,225)
Contractual maturity of 1 to 3 years, Fair Value	71,550
Commercial Paper [Member]
Schedule Of Available For Sale Securities [Line Items]
Contractual maturity of 0 to 1 years, Amortized Cost	102,465
Contractual maturity of 0 to 1 years, Fair Value	102,465
Corporate Debt Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Contractual maturity of 0 to 1 years, Amortized Cost	8,866
Contractual maturity of 0 to 1 years, Unrealized Loss	(79)
Contractual maturity of 0 to 1 years, Fair Value	8,787
Contractual maturity of 1 to 3 years, Amortized Cost	42,635
Contractual maturity of 1 to 3 years, Unrealized Loss	(196)
Contractual maturity of 1 to 3 years, Fair Value	$ 42,439

Leases (Details)

Leases (Details)	1 Months Ended	9 Months Ended
Leases (Details)	Nov. 30, 2021	Sep. 30, 2022 USD ($) Lease
Burnaby, British Columbia [Member]
Lessee Lease Description [Line Items]
Number of operating leases \| Lease		1
Operating lease expiration date	Jun. 30, 2032
Operating lease, description		The Company has one operating lease for research laboratories and office space in Burnaby, British Columbia. In October 2020, the Company entered into a lease amendment for a 21-month committed term from October 1, 2020 to June 30, 2022 and a renewal option for a portion of the facility for a 5-year term that was reasonably certain of exercise was included in the determination of the right-of-use asset and lease liability. In November 2021, the Company entered into an agreement to extend the lease for an additional 10-year term to June 30, 2032.
Needham Massachusetts [Member]
Lessee Lease Description [Line Items]
Operating lease, not yet commenced, description		In July 2022, the Company entered into a lease agreement for office space in Needham, Massachusetts. As of September 30, 2022, the lease has not yet commenced; the Company began occupying the premise in October 2022.
Operating lease, not yet commenced, term of contract		5 years
Needham Massachusetts [Member] \| Minimum [Member]
Lessee Lease Description [Line Items]
Operating lease not yet commenced, base rent		$ 751,000
Needham Massachusetts [Member] \| Maximum [Member]
Lessee Lease Description [Line Items]
Operating lease not yet commenced, base rent		$ 819,000

Leases - Schedule of Cost Compo

Leases - Schedule of Cost Components of Operating Lease (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Leases [Abstract]
Operating lease expense	$ 238	$ 140	$ 714	$ 419
Variable lease expense	$ 195	$ 185	$ 578	$ 559
Remaining lease term (years)	9 years 9 months	5 years 9 months	9 years 9 months	5 years 9 months
Discount rate	3.42%	2.45%	3.42%	2.45%

Leases - Future Minimum Lease P

Leases - Future Minimum Lease Payments (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2022	$ 213
2023	852
2024	890
2025	940
2026	990
2027 and thereafter	6,210
Total future minimum lease payments	10,095
Less: imputed interest	(1,596)
Less: future lease incentives reasonably certain of use	(1,342)
Present value of lease liabilities	$ 7,157

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses - Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Payables And Accruals [Abstract]
Trade payables	$ 3,082	$ 3,824
Employee compensation, benefits, and related accruals	4,221	5,940
Consulting and contracted research	7,220	3,550
Professional fees	969	285
Other	45	118
Total	$ 15,537	$ 13,717

Share Capital (Details)

Share Capital (Details) - USD ($) $ / shares in Units, $ in Thousands

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Jun. 30, 2022

Mar. 31, 2022

Jan. 31, 2022

Sep. 30, 2021

Mar. 31, 2021

Jan. 31, 2021

Mar. 31, 2018

Jun. 30, 2022

Mar. 31, 2022

Sep. 30, 2021

Mar. 31, 2021

Sep. 30, 2022

Dec. 31, 2018

Share Capital [Line Items]

Warrants outstanding to purchase common stock

1,081,081

3,103,864

Warrants exercise description

The Company may not affect the exercise of any pre-funded warrant, and a holder will not be entitled to exercise any portion of any pre-funded warrant that, upon giving effect to such exercise, would cause: (i) the aggregate number of common shares beneficially owned by such holder, together with its affiliates, to exceed 4.99% of the total number of common shares outstanding immediately after giving effect to the exercise; or (ii) the combined voting power of the Company’s securities beneficially owned by such holder, together with its affiliates, to exceed 4.99% of the combined voting power of all of the Company’s securities immediately outstanding after giving effect to the exercise, which percentage may be changed at the holder’s election to a higher or lower percentage not in excess of 19.99% upon at least 61 days’ notice to the Company.

Series 1 Preferred Shares

Share Capital [Line Items]

Conversion of shares

1,016,000

1,852,000

BVF Partners L.P [Member] | Exchange Agreement [Member] | Series 1 Preferred Shares

Share Capital [Line Items]

Shares issued

2,868,000

Preferred shares convertible into common shares

one-for-one

Common Shares [Member]

Share Capital [Line Items]

Shares issued

9,098,362

258,986

275,337

5,868,135

Conversion of shares

1,016,000

1,852,000

Common Shares [Member] | BVF Partners L.P [Member] | Exchange Agreement [Member]

Share Capital [Line Items]

Shares cancelled

2,868,000

Jefferies and Stifel [Member] | Underwritten Public Offering [Member]

Share Capital [Line Items]

Shares issued

5,135,135

Shares price

$ 18.50

Warrants outstanding to purchase common stock

1,081,081

Warrants issued price per pre funded warrant

$ 18.4999

Sale proceeds of common shares

$ 107,922

Warrants exercise price per common share

$ 0.0001

Number of warrants exercised

Jefferies and Stifel [Member] | ATM [Member]

Share Capital [Line Items]

Sale proceeds of common shares

$ 10,693

Jefferies and Stifel [Member] | ATM [Member] | Maximum [Member]

Share Capital [Line Items]

Gross proceeds from issuable of common stock

$ 250,000

Jefferies and Stifel [Member] | ATM [Member] | Common Shares [Member]

Share Capital [Line Items]

Shares issued

733,000

Jefferies and Stifel [Member] | Over Allotment [Member]

Share Capital [Line Items]

Shares issued

810,810

Jefferies, Stifel, J.P. Morgan Securities LLC and SVB Securities LLC [Member] | Underwritten Public Offering [Member]

Share Capital [Line Items]

Shares issued

9,098,362

Shares price

$ 30.50

Warrants outstanding to purchase common stock

327,868

Warrants issued price per pre funded warrant

$ 30.4999

Sale proceeds of common shares

$ 269,890

Warrants exercise price per common share

$ 0.0001

Jefferies, Stifel, J.P. Morgan Securities LLC and SVB Securities LLC [Member] | Over Allotment [Member]

Share Capital [Line Items]

Shares issued

1,229,508

Neurocrine Biosciences [Member] | Common Shares [Member]

Share Capital [Line Items]

Shares issued

258,986

275,337

Sale proceeds of common shares

$ 8,250

$ 5,500

Aggregate purchase price per share

$ 31.855

$ 19.9755

License and Collaboration Agreement [Member] | Neurocrine Biosciences [Member]

Share Capital [Line Items]

Premium

$ 374

$ 770

Share Capital - Schedule of Pre

Share Capital - Schedule of Pre-Funded Warrants (Details) - $ / shares	Sep. 30, 2022	Sep. 30, 2021
Share Capital [Line Items]
Pre-Funded Warrants to Purchase Common Shares	3,103,864	1,081,081
March 2021
Share Capital [Line Items]
Pre-Funded Warrants to Purchase Common Shares	1,081,081
Price per Pre-Funded Warrant	$ 18.4999
Exercise Price	$ 0.0001
October 2021
Share Capital [Line Items]
Pre-Funded Warrants to Purchase Common Shares	1,694,915
Price per Pre-Funded Warrant	$ 29.4999
Exercise Price	$ 0.0001
June 2022
Share Capital [Line Items]
Pre-Funded Warrants to Purchase Common Shares	327,868
Price per Pre-Funded Warrant	$ 30.4999
Exercise Price	$ 0.0001

Share Capital - Stock Option Ac

Share Capital - Stock Option Activity (Details) - shares	3 Months Ended		9 Months Ended
Share Capital - Stock Option Activity (Details) - shares	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Options Outstanding, Beginning balance	7,234,460	5,771,051	5,638,232	4,758,997
Number of Options, Granted	102,000	236,200	2,079,845	1,730,650
Number of Options, Exercised	(369,334)	(41,974)	(718,472)	(386,708)
Number of Options, Forfeited, cancelled or expired	(21,357)	(45,843)	(53,836)	(183,505)
Number of Options Outstanding, Ending balance	6,945,769	5,919,434	6,945,769	5,919,434
Number of Options Exercisable, End of period	3,391,011	3,068,278	3,391,011	3,068,278

Share Capital - Stock Option _2

Share Capital - Stock Option Activity (Parenthetical) (Details) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Options exercised for Number of Common Shares for cash	65,844	61,072
Common stock issued for cashless exercise	468,598	196,206
Cashless exercise of stock options	652,628	325,636

Share Capital - Fair Value Assu

Share Capital - Fair Value Assumptions for Stock Options (Details) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Fair Value Assumptions For Stock Options [Abstract]
Average risk-free interest rate	3.20%	1%	2.19%	1.16%
Expected volatility	70%	68%	70%	68%
Average expected term (in years)	4 years 11 months 1 day	6 years 9 months 7 days	6 years 1 month 24 days	6 years 8 months 8 days
Expected dividend yield	0%	0%	0%	0%
Weighted average fair value of stock options granted	$ 21.63	$ 10.74	$ 19.40	$ 12.41

Revenue - Schedule of Collabora

Revenue - Schedule of Collaboration Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation Of Revenue [Line Items]
Revenue	$ 132	$ 8,124	$ 9,434	$ 14,700
Collaboration Revenue [Member]
Disaggregation Of Revenue [Line Items]
Revenue	132	8,124	9,434	14,700
Neurocrine Biosciences [Member] \| Collaboration Revenue [Member]
Disaggregation Of Revenue [Line Items]
Recognition of the transaction price		823	372	1,440
Research and development services	$ 132	2,031	1,938	4,990
Milestone payments		$ 5,270	$ 7,124	5,270
Pacira BioSciences [Member] \| Collaboration Revenue [Member]
Disaggregation Of Revenue [Line Items]
Milestone payments				$ 3,000

Revenue - Additional Informatio

Revenue - Additional Information (Details) - USD ($)	1 Months Ended		3 Months Ended			9 Months Ended		12 Months Ended
Revenue - Additional Information (Details) - USD ($)	Jan. 31, 2022	Sep. 30, 2021	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2019
Disaggregation Of Revenue [Line Items]
Revenue			$ 132,000		$ 8,124,000	$ 9,434,000	$ 14,700,000
Collaboration Revenue [Member]
Disaggregation Of Revenue [Line Items]
Revenue			132,000		8,124,000	9,434,000	14,700,000
Neurocrine Biosciences [Member] \| Collaboration Revenue [Member]
Disaggregation Of Revenue [Line Items]
Research and development services			132,000		2,031,000	1,938,000	4,990,000
Milestone payments					5,270,000	7,124,000	5,270,000
Pacira BioSciences [Member] \| Collaboration Revenue [Member]
Disaggregation Of Revenue [Line Items]
Milestone payments							3,000,000
Development Services Under the Initial Development Program For DTCs [Member] \| Neurocrine Biosciences [Member] \| Collaboration Revenue [Member]
Disaggregation Of Revenue [Line Items]
Revenue			0		$ 823,000	372,000	1,440,000
License and Collaboration Agreement [Member] \| Neurocrine Biosciences [Member]
Disaggregation Of Revenue [Line Items]
Upfront payment received in cash								$ 30,000,000
Upfront payment received in equity investment								20,000,000
Equity investment measured at fair value								16,667,000
Collaborate agreement premium related to equity investment								3,333,000
Transaction price allocated to performance obligations								33,333,000
Milestone Payment Received	$ 15,000,000	$ 10,000,000
Milestone Payment Received in Cash	6,750,000	4,500,000
Milestone Payment Received in Equity Investment	8,250,000	5,500,000
Equity investment measure at fair value	7,876,000	4,730,000
Premium	374,000	770,000
Performance obligation related to milestone	0	0
Revenue	$ 6,750,000	$ 4,500,000
Potential milestone payments receivable			1,667,500,000			$ 1,667,500,000
Percentage of option to co-fund development costs upon achievement of certain milestones						50%
License and Collaboration Agreement [Member] \| Neurocrine Biosciences [Member] \| Regulatory Milestone [Member]
Disaggregation Of Revenue [Line Items]
Potential milestone payments receivable			1,067,500,000			$ 1,067,500,000
License and Collaboration Agreement [Member] \| Neurocrine Biosciences [Member] \| Sales Based Milestone [Member]
Disaggregation Of Revenue [Line Items]
Potential milestone payments receivable			$ 600,000,000			$ 600,000,000
License and Collaboration Agreement [Member] \| Exclusive License to XEN901 and Exclusive License to DTCs [Member] \| Neurocrine Biosciences [Member]
Disaggregation Of Revenue [Line Items]
Transaction price allocated to performance obligations								$ 28,807,000
License and Collaboration Agreement [Member] \| Development Services Under the Initial Development Program For DTCs [Member] \| Neurocrine Biosciences [Member]
Disaggregation Of Revenue [Line Items]
Transaction price allocated to performance obligations				$ 5,025,000
Variable consideration allocated to performance obligation				$ 499,000
Asset Purchase Agreement [Member] \| Pacira BioSciences [Member] \| XEN402 [Member]
Disaggregation Of Revenue [Line Items]
Milestone payments							1,000,000
Milestone payment due on initiation of Phase 1b clinical trial							$ 2,000,000

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	1 Months Ended		9 Months Ended
Commitments and Contingencies (Details) - USD ($)	Aug. 31, 2020	Aug. 31, 2015	Sep. 30, 2022
Asset Purchase Agreement [Member] \| 1st Order Pharmaceuticals, Inc. [Member]
Commitments and Contingencies [Line Items]
Milestone payment paid			$ 600,000
Royalty obligation			0
Asset Purchase Agreement [Member] \| 1st Order Pharmaceuticals, Inc. [Member] \| Clinical Development Milestones [Member]
Commitments and Contingencies [Line Items]
Future potential payments	$ 900,000
Asset Purchase Agreement [Member] \| 1st Order Pharmaceuticals, Inc. [Member] \| Regulatory Milestone [Member] \| Maximum [Member]
Commitments and Contingencies [Line Items]
Future potential payments	6,000,000
Asset Purchase Agreement [Member] \| 1st Order Pharmaceuticals, Inc. [Member] \| Other Milestones [Member]
Commitments and Contingencies [Line Items]
Future potential payments	$ 500,000
Priority Access Agreement with Medpace Inc. [Member]
Commitments and Contingencies [Line Items]
Service agreement, term		5 years
Committed service obligation		$ 7,000,000	1,479,000
Contractual obligation paid			$ 5,521,000